Method for using lipoprotein associated coagulation inhibitor to treat sepsis
OwnerAbla A. Creasey, George J. Brozeinventors
Life of this patent
Estimating the term…
Abstract
A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to pateints. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
Claims40
A method of treating sepsis-associated DIC comprising:
- administering to a patient who has sepsis-associated DIC a therapeutically effective amount of LACI in the absence of heparin.
A method for treating septic patients who do not have DIC, comprising:
- administering to a septic patient who does not have DIC a therapeutically effective amount of LACI.
A prophylactic method for decreasing the risk and severity of sepsis comprising:
- administering to a patient susceptible to sepsis a prophylactically effective amount of LACI.
A method for prophylactically and therapeutically treating acute inflammation, including sepsis and septic shock, comprising administering to a patient a therapeutically effective amount of LACI.
A method for treating a disease state in which TNF, IL-1 and other cytokines up-regulate tissue factor comprising administering LACI.
A method for treating inflammation comprising administering to a patient a therapeutically effective amount of LACI or a fragment thereof.
Dependencies are inferred from the claim text.